Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fangzhi Decoction (防芷汤, Fáng Zhĭ Tāng) is a traditional Chinese medicine (TCM) formulation being evaluated for its efficacy in preventing gastrointestinal toxicity associated with concurrent chemoradiotherapy (CCRT) in patients with locally advanced cervical cancer. In clinical studies, Fangzhi Decoction has demonstrated the ability to significantly reduce the incidence of severe (Grade 3-4) gastrointestinal toxicity and diarrhea, improve patients' physical condition (as measured by Karnofsky Performance Status), and enhance treatment compliance and immediate therapeutic benefits compared to other treatments like Kangfuxin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fangzhi decoction.